Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Alio Gold Inc. (TSX:ALO) is 54.086200. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Alio Gold Inc. (TSX:ALO) is 54.163500. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 52.356300.

At some point, individual investors may find themselves routinely falling prey to the lure of performance chasing. It can be highly tempting to want to be a part of a near-term stock run to the upside. Short-term investors may only be interested in these types of moves, but longer-term investors may want to be a bit more cautious. Chasing performance may end up leading the investor away from previously defined goals and the overall strategy. Investors who are committed to achieving long-term success may occasionally need to reshuffle the deck when the short-term clatter becomes too noisy.

At the time of writing, Alio Gold Inc. (TSX:ALO) has a Piotroski F-Score of 6. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

Investors may be interested in viewing the Gross Margin score on shares of Alio Gold Inc. (TSX:ALO). The name currently has a score of 58.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative. The Q.i. Value of Alio Gold Inc. is 31.00000. The Q.i. Value is a helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of Alio Gold Inc. (TSX:ALO) is 2280. A company with a low rank is considered a good company to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Alio Gold Inc. (TSX:ALO) is 1907. The lower the ERP5 rank, the more undervalued a company is thought to be.

Some of the best financial predictions are formed by using a variety of financial tools. The Price Range 52 Weeks is one of the tools that investors use to determine the lowest and highest price at which a stock has traded in the previous 52 weeks. The Price Range of Alio Gold Inc. (TSX:ALO) over the past 52 weeks is 0.334000. The 52-week range can be found in the stock’s quote summary.

We can now take a quick look at some historical stock price index data. Alio Gold Inc. (TSX:ALO) presently has a 10 month price index of 0.38032. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 0.46250, the 24 month is 0.55106, and the 36 month is 0.35479. Narrowing in a bit closer, the 5 month price index is 0.59815, the 3 month is 0.57942, and the 1 month is currently 0.91519.

Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow. The FCF Growth of Alio Gold Inc. (TSX:ALO) is 0.046792. Free cash flow (FCF) is the cash produced by the company minus capital expenditure. This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends. The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow. The FCF Score of Alio Gold Inc. is 3.557076. Experts say the higher the value, the better, as it means that the free cash flow is high, or the variability of free cash flow is low or both.

The 12 month volatility of Aevi Genomic Medicine, Inc. (NasdaqGM:GNMX) is 64.121800. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Aevi Genomic Medicine, Inc. (NasdaqGM:GNMX) is 79.264100. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 75.149900.

Creating a diversified stock portfolio is one way that investors may combat the unknown. Appropriate levels of risk that include different market scenarios might vary from one individual investor to the next. Investors may need to careful that they do not become too reliant on one big position. When that position is producing returns, it can be easy to assume that the holding will continue to produce positive results. If the portfolio is weighted too heavily on one or two big positions, an overall market downturn may send the investor reeling. Finding that proper portfolio balance is typically what dedicated investors strive for.

At the time of writing, Aevi Genomic Medicine, Inc. (NasdaqGM:GNMX) has a Piotroski F-Score of 2. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

Some of the best financial predictions are formed by using a variety of financial tools. The Price Range 52 Weeks is one of the tools that investors use to determine the lowest and highest price at which a stock has traded in the previous 52 weeks. The Price Range of Aevi Genomic Medicine, Inc. (NasdaqGM:GNMX) over the past 52 weeks is 0.648000. The 52-week range can be found in the stock’s quote summary.

Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow. The FCF Growth of Aevi Genomic Medicine, Inc. (NasdaqGM:GNMX) is 0.249388. Free cash flow (FCF) is the cash produced by the company minus capital expenditure. This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends. The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow. The FCF Score of Aevi Genomic Medicine, Inc. is 0.918710. Experts say the higher the value, the better, as it means that the free cash flow is high, or the variability of free cash flow is low or both.

We can now take a quick look at some historical stock price index data. Aevi Genomic Medicine, Inc. (NasdaqGM:GNMX) presently has a 10 month price index of 1.13846. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 0.87475, the 24 month is 0.30904, and the 36 month is 0.16958. Narrowing in a bit closer, the 5 month price index is 1.05327, the 3 month is 1.19091, and the 1 month is currently 0.78594.

Investors may be interested in viewing the Gross Margin score on shares of Aevi Genomic Medicine, Inc. (NasdaqGM:GNMX). The name currently has a score of 50.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative. The Q.i. Value of Aevi Genomic Medicine, Inc. is 94.00000. The Q.i. Value is a helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of Aevi Genomic Medicine, Inc. (NasdaqGM:GNMX) is 19122. A company with a low rank is considered a good company to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Aevi Genomic Medicine, Inc. (NasdaqGM:GNMX) is 16883. The lower the ERP5 rank, the more undervalued a company is thought to be.